Pfizer (PFE) Share-based Compensation (2009 - 2026)
Pfizer (PFE) posted quarterly Share-based Compensation of $272.0 million for Q1 2026, up 60.0% year-over-year from $170.0 million in Q1 2025, and up 195.1% quarter-over-quarter from -$286.0 million in Q4 2025.
Pfizer (PFE) Share-based Compensation (2009 - 2026) Analysis & Trends
Pfizer (PFE) has reported Share-based Compensation for 18 consecutive years, with $272.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation rose 60.0% year-over-year to $272.0 million; the TTM figure through Mar 2026 stood at $390.0 million (down 69.91% YoY), while the FY2025 annual figure was $288.0 million, down 67.16% from the prior year.
- Share-based Compensation rose to $272.0 million in Q1 2026 per PFE's latest filing, from -$286.0 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $700.0 million in Q3 2024 and bottomed at -$286.0 million in Q4 2025.
- Historically, Share-based Compensation has averaged $194.0 million across 5 years, with a median of $203.0 million in 2025.
- Annual changes were most pronounced in 2022 — Share-based Compensation plunged 72.19% — and 2024, when it jumped 109.52%.
- Pfizer's Share-based Compensation stood at $287.0 million in 2022, then declined by 26.83% to $210.0 million in 2023, then soared by 233.33% to $700.0 million in 2024, then sank by 140.86% to -$286.0 million in 2025, then surged by 195.1% to $272.0 million in 2026.
- Business Quant data shows PFE's Share-based Compensation at $272.0 million in Q1 2026, -$286.0 million in Q4 2025, and $201.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 458.00 Mn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 166.00 Mn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 298.00 Mn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 165.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 231.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 249.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 249.00 Mn |
| Jun 28, 2026 | 249.00 Mn |
| Mar 29, 2026 | 272.00 Mn |
| Mar 29, 2026 | 272.00 Mn |
| Dec 31, 2025 | -286.00 Mn |
| Dec 31, 2025 | -286.00 Mn |
| Sep 28, 2025 | 201.00 Mn |
| Sep 28, 2025 | 201.00 Mn |
| Jun 29, 2025 | 203.00 Mn |
| Jun 29, 2025 | 203.00 Mn |
| Mar 30, 2025 | 170.00 Mn |
| Mar 30, 2025 | 170.00 Mn |
| Sep 29, 2024 | 700.00 Mn |
| Sep 29, 2024 | 700.00 Mn |
| Jun 30, 2024 | 206.00 Mn |
| Jun 30, 2024 | 206.00 Mn |
| Mar 31, 2024 | 220.00 Mn |
| Mar 31, 2024 | 220.00 Mn |
| Dec 31, 2023 | 210.00 Mn |
| Dec 31, 2023 | 210.00 Mn |